Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

Phase 2 Recruiting 234 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.

Timeline

Start: 2026-01-14
Primary completion: 2026-07
Completion: 2027-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-9563	Unknown	—	—

Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

Summary

Timeline

Drugs

Indications